ATE491021T1 - Verfahren zur produktion eines zytotoxischen lymphozyten - Google Patents

Verfahren zur produktion eines zytotoxischen lymphozyten

Info

Publication number
ATE491021T1
ATE491021T1 AT03712887T AT03712887T ATE491021T1 AT E491021 T1 ATE491021 T1 AT E491021T1 AT 03712887 T AT03712887 T AT 03712887T AT 03712887 T AT03712887 T AT 03712887T AT E491021 T1 ATE491021 T1 AT E491021T1
Authority
AT
Austria
Prior art keywords
cytotoxic lymphocyte
producing
cytotoxic
lymphocyte
fibronectin
Prior art date
Application number
AT03712887T
Other languages
English (en)
Inventor
Hiroaki Sagawa
Mitsuko Ideno
Ikunoshin Kato
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of ATE491021T1 publication Critical patent/ATE491021T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT03712887T 2002-03-25 2003-03-25 Verfahren zur produktion eines zytotoxischen lymphozyten ATE491021T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002084414 2002-03-25
PCT/JP2003/003575 WO2003080817A1 (fr) 2002-03-25 2003-03-25 Procede de production de lymphocyte cytotoxique

Publications (1)

Publication Number Publication Date
ATE491021T1 true ATE491021T1 (de) 2010-12-15

Family

ID=28449211

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03712887T ATE491021T1 (de) 2002-03-25 2003-03-25 Verfahren zur produktion eines zytotoxischen lymphozyten

Country Status (14)

Country Link
US (3) US8728811B2 (de)
EP (3) EP2305793B1 (de)
JP (1) JP4406566B2 (de)
KR (2) KR100895231B1 (de)
CN (3) CN102321579A (de)
AT (1) ATE491021T1 (de)
AU (2) AU2003221073B2 (de)
CA (1) CA2479288C (de)
DE (1) DE60335253D1 (de)
EA (1) EA010434B1 (de)
ES (3) ES2356814T3 (de)
MX (1) MXPA04009287A (de)
TW (2) TWI334442B (de)
WO (1) WO2003080817A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100888915B1 (ko) 2001-08-15 2009-03-16 다카라 바이오 가부시키가이샤 항원특이적 세포상해성 ｔ 세포 확대배양방법
JP4406566B2 (ja) 2002-03-25 2010-01-27 タカラバイオ株式会社 細胞傷害性リンパ球の製造方法
KR101331746B1 (ko) * 2003-08-22 2013-11-20 다카라 바이오 가부시키가이샤 세포 상해성 림프구의 제조 방법
GB0409775D0 (en) * 2004-04-30 2004-06-09 Mabtech Ab Assay
EP1916302A4 (de) 2005-08-17 2009-10-21 Takara Bio Inc Verfahren zur herstellung von lymphozyten
JP4741906B2 (ja) * 2005-08-31 2011-08-10 タカラバイオ株式会社 リンパ球の製造方法
JP5156382B2 (ja) * 2005-09-30 2013-03-06 タカラバイオ株式会社 Ｔ細胞集団の製造方法
EP2028266A4 (de) * 2006-06-09 2010-08-11 Takara Bio Inc Verfahren zur herstellung von lymphozyten
WO2008008435A2 (en) * 2006-07-14 2008-01-17 Rutgers, The State University Methods, systems, and compositions for extracellular matrix production
US20110158954A1 (en) * 2007-03-09 2011-06-30 Mitsuko Ideno Method for producing gamma delta t cell population
US20100247579A1 (en) * 2007-05-11 2010-09-30 Hiroshi Shiku Therapeutic agent for cancer
US8470966B2 (en) * 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
EP2267118A4 (de) 2008-03-27 2013-08-28 Takara Bio Inc Verfahren zur herstellung einer transfizierten zelle
WO2011024791A1 (ja) 2009-08-25 2011-03-03 タカラバイオ株式会社 レチノイン酸存在下でのｔ細胞集団の製造方法
WO2011030851A1 (ja) 2009-09-11 2011-03-17 タカラバイオ株式会社 ナチュラルキラー細胞の製造方法
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
EP2510086A4 (de) * 2009-12-08 2013-05-22 Wolf Wilson Mfg Corp Verbesserte verfahren für zellkulturen für adoptive zelltherapien
CN103547278B (zh) 2011-05-19 2015-11-25 东丽株式会社 免疫诱导剂
WO2017176932A1 (en) 2016-04-08 2017-10-12 Emory University Methods of treating cancer and infectious diseases using cell based therapies
KR102437703B1 (ko) 2016-07-29 2022-08-26 다카라 바이오 가부시키가이샤 줄기세포의 제조에 사용되는 피브로넥틴 프래그먼트
CN110199017A (zh) 2017-01-20 2019-09-03 国立大学法人京都大学 CD8α+β+细胞毒性T细胞的制备方法
US12018276B2 (en) 2018-01-25 2024-06-25 Takara Bio Inc. Lymphocyte production method
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
JPWO2021200901A1 (de) 2020-03-31 2021-10-07
CN121646636A (zh) 2023-06-02 2026-03-10 国立大学法人京都大学 T细胞祖细胞产生方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
EP0287652B1 (de) 1986-10-20 1994-01-12 Life Technologies Inc. Serumfreies medium zur proliferation von lymphokin-aktivierten töterzellen
US5019646A (en) * 1987-08-25 1991-05-28 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
JP2561131B2 (ja) * 1988-06-30 1996-12-04 寳酒造株式会社 細胞接着活性ポリペプチド
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5198423A (en) 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
GR1001034B (el) 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
JP3104178B2 (ja) 1990-03-30 2000-10-30 寶酒造株式会社 機能性ポリペプチド
JPH04297494A (ja) * 1991-03-26 1992-10-21 Fuji Photo Film Co Ltd ペプチド誘導体とその用途
JP2729712B2 (ja) 1991-04-23 1998-03-18 寳酒造株式会社 機能性ポリペプチド
JPH07102131B2 (ja) 1991-07-15 1995-11-08 日本石油株式会社 ヒトリンパ球の癌細胞に対する傷害活性を高める方法
JPH06172203A (ja) 1992-12-02 1994-06-21 Takara Shuzo Co Ltd フィブロネクチンレセプター産生異常細胞抑制剤
JPH06306096A (ja) * 1993-02-26 1994-11-01 Fuji Photo Film Co Ltd ペプチド誘導体及びその用途
GB9315810D0 (en) 1993-07-30 1993-09-15 Univ London Stabilised materials
DE4336399A1 (de) 1993-10-26 1995-04-27 Augustinus Dr Med Bader Verfahren zur Verbesserung der Matrixbedingungen bipolar adhärierter Hepatozyten und zur Herstellung eines entsprechend konfigurierten Zellkulturkits
US6821778B1 (en) * 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
GB9413029D0 (en) 1994-06-29 1994-08-17 Common Services Agency Stem cell immobilisation
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
JP3351471B2 (ja) * 1994-11-29 2002-11-25 タカラバイオ株式会社 形質転換細胞の製造方法
WO1996016674A1 (en) 1994-12-01 1996-06-06 New England Deaconess Hospital Corporation In vitro t-lymphopoiesis system
CA2220226C (en) 1995-05-04 2008-10-21 Carl H. June Improved methods for transfecting t cells
US6692964B1 (en) * 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) * 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
JP3391941B2 (ja) 1995-06-15 2003-03-31 アサヒビール株式会社 余剰汚泥の処理方法
WO1997001194A1 (de) 1995-06-21 1997-01-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Elektrochemisches festelektrolyt-zellsystem
JPH0925299A (ja) 1995-07-13 1997-01-28 Sumitomo Electric Ind Ltd Ｃｄ４４リガンド
CA2227327A1 (en) 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
DE19537494C2 (de) 1995-09-25 1997-10-02 Desitin Arzneimittel Gmbh Kreatin zum Schutz von neuralem Gewebe
ATE325533T1 (de) 1995-09-29 2006-06-15 Univ Indiana Res & Tech Corp Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen
KR100353115B1 (ko) 1995-11-13 2003-01-06 다카라츠죠 가부시키가이샤 레트로바이러스를사용한표적세포내로의유전자도입방법
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
CA2247131A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
ATE476496T1 (de) * 1996-03-04 2010-08-15 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
JPH1029952A (ja) 1996-07-16 1998-02-03 Takara Shuzo Co Ltd ヒト免疫不全ウイルス感染の制御用組成物および制御方法
JP2001501085A (ja) 1996-09-23 2001-01-30 オントジニー インコーポレーテッド 造血幹細胞およびこのような細胞を生成するための方法
CA2278189A1 (en) 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
JP3591286B2 (ja) 1997-04-24 2004-11-17 セイコーエプソン株式会社 タイミング調整方法、印字装置及び調整パターン作成方法
TWI239352B (en) 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
DE69838490T2 (de) 1997-12-24 2008-02-07 Bracco International B.V. Peptide chelatoren die nach der koordination mit einem metall zu einem vorherrschenden einzel-stereoisomeren führen
WO1999033869A2 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
JP2002522513A (ja) 1998-08-11 2002-07-23 アメリカ合衆国 哺乳動物細胞を形質導入する方法およびそれに関連する産物
CN1225285C (zh) * 1999-03-23 2005-11-02 宝生物工程株式会社 基因治疗剂
US6797514B2 (en) * 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
JP3904374B2 (ja) 2000-02-29 2007-04-11 独立行政法人科学技術振興機構 キラー活性を増強したリンパ球
EP1312670A4 (de) 2000-08-16 2005-11-30 Takara Bio Inc Methode zur extensiven kultur von antigen-spezifischen cytotoxischen t-zellen
WO2002098361A2 (en) * 2001-06-01 2002-12-12 Xcyte Therapies, Inc. T cell induced tissue repair and regeneration
KR100888915B1 (ko) * 2001-08-15 2009-03-16 다카라 바이오 가부시키가이샤 항원특이적 세포상해성 ｔ 세포 확대배양방법
JP4759890B2 (ja) 2001-09-12 2011-08-31 大日本印刷株式会社 パール調印刷物の印刷濃度管理方法
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
JP4406566B2 (ja) * 2002-03-25 2010-01-27 タカラバイオ株式会社 細胞傷害性リンパ球の製造方法
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
KR101331746B1 (ko) 2003-08-22 2013-11-20 다카라 바이오 가부시키가이샤 세포 상해성 림프구의 제조 방법

Also Published As

Publication number Publication date
JPWO2003080817A1 (ja) 2005-07-28
AU2008243221B2 (en) 2011-10-27
MXPA04009287A (es) 2005-01-25
CN101735981B (zh) 2013-01-02
CN102321579A (zh) 2012-01-18
ES2356814T3 (es) 2011-04-13
US8728811B2 (en) 2014-05-20
CN101735981A (zh) 2010-06-16
KR100786054B1 (ko) 2007-12-17
EP1496109A4 (de) 2006-07-19
EP1496109A1 (de) 2005-01-12
CA2479288A1 (en) 2003-10-02
CN1656215A (zh) 2005-08-17
TW201043699A (en) 2010-12-16
EA200401242A1 (ru) 2005-04-28
KR100895231B1 (ko) 2009-05-04
ES2396447T3 (es) 2013-02-21
US8975070B2 (en) 2015-03-10
EP2305793B1 (de) 2012-10-17
US20050227354A1 (en) 2005-10-13
CA2479288C (en) 2015-02-24
WO2003080817A1 (fr) 2003-10-02
EP2305796B1 (de) 2012-10-24
HK1079543A1 (zh) 2006-04-07
HK1144105A1 (en) 2011-01-28
EP1496109B1 (de) 2010-12-08
AU2003221073B2 (en) 2008-08-21
ES2397319T3 (es) 2013-03-06
DE60335253D1 (de) 2011-01-20
EP2305796A1 (de) 2011-04-06
AU2003221073A1 (en) 2003-10-08
KR20070015620A (ko) 2007-02-05
TW200400265A (en) 2004-01-01
JP4406566B2 (ja) 2010-01-27
TWI334442B (en) 2010-12-11
AU2008243221A1 (en) 2008-12-04
US20080227204A1 (en) 2008-09-18
KR20040099352A (ko) 2004-11-26
EP2305793A1 (de) 2011-04-06
CN100591760C (zh) 2010-02-24
US20140212972A1 (en) 2014-07-31
EA010434B1 (ru) 2008-08-29

Similar Documents

Publication Publication Date Title
ATE491021T1 (de) Verfahren zur produktion eines zytotoxischen lymphozyten
DE60328492D1 (de) Verfahren zur erzeugung von nanoteilchen
ATE331695T1 (de) Verfahren und vorrichtung zur herstellung von mineralwolle und so hergestellte mineralwolleprodukte
ATE544754T1 (de) Verfahren zur herstellung von ivabradinhydrochlorid
DE60313375D1 (de) Einrichtung und Verfahren zur Herstellung einer Rasch Erstarrten Legierung für Magnete
DE60223032D1 (de) Vorrichtung zur herstellung von verbundkonstruktionen und verfahren zur herstellung derselben
DE50113774D1 (de) Fahrzeugverbundbauteil sowie Verfahren und Vorrichtung zur Herstellung des Fahrzeugverbundbauteils
ATE360653T1 (de) Verfahren zur herstellung von polyisobutenen
ATE458046T1 (de) Verfahren zur herstellung zytotoxischer lymphozyten
TW200741000A (en) Method of producing lymphocytes
DE60311990D1 (de) Verfahren zur herstellung eines virus inaktivierten thrombin präparates
ATE386717T1 (de) Ein verfahren zur herstellung von perindopril, analogen verbindungen dazu sowie salzen davon unter verwendung von 2,5-dioxooxazolidin- zwischenprodukten
DE602004026253D1 (de) Verfahren zur Herstellung von Stahlbrammen mit ultra-geringem Kohlenstoffgehalt
EP1848580A4 (de) Vorrichtung und verfahren zur herstellung von wellpappe und kaschiertem karton sowie darauf beruhende zusammensetzungen
ATE506351T1 (de) Verfahren zur herstellung von 10,11-dihydro-10- oxo-5h-dibenzoäb,füazepin-5-carboxamid
EP1441978A4 (de) Verfahren und vorrichtung zur erzeugung von wasserstoffgas
ATE360610T1 (de) Verfahren zur herstellung von cilastatin
ATE323677T1 (de) Verfahren zur herstellung von 4-amino-2,5- bisheterocyclylchinazolinen
DE60234002D1 (de) Verfahren zur Herstellung von Verbundmaterial
DE60229198D1 (de) Verfahren zur Herstellung eines Verbundwerkstoffes
DE60334180D1 (de) Verfahren zur Herstellung einer Radlaufschale und damit hergestellte Radlaufschale
DE60230422D1 (de) Verfahren zur herstellung von kohlenwasserstoffen
ATE335686T1 (de) Verfahren und rohling zur herstellung eines gekrümmten kurvenelements, gekrümmtes kurvenelement, kurveneinheit mit einem gekrümmten kurvenelement und des weiteren förderbahn mit solch einer kurveneinheit
ATE437879T1 (de) Verfahren zur herstellung von imipenem
DE60332739D1 (de) Rekombinante typ-ii-restriktionsendonukleasen, mme i und verwandte endonukleasen sowie verfahren zur herstellung davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties